InBreakout VenturesbyRenee Shenton·Dec 13, 2023Synergy in Drug DiscoveryWhy Breakout invested in A-Alpha Bio
InBreakout VenturesbyRenee Shenton·May 17, 2023Breakout Launches Nucleate Partnership, Announces 2023 Fellows CohortBuilding the next generation of biotech leaders
InBreakout VenturesbyRenee Shenton·May 2, 2023Unlocking the Power of RNA: Overcoming Manufacturing ChallengesWhy Breakout invested in EnPlusOne Biosciences
InBreakout VenturesbyRenee Shenton·Oct 18, 2022DNA synthesis — a technical primerAn engineering, not a biology problem
InBreakout VenturesbyRenee Shenton·Dec 9, 2021Breakout Ventures raises $112.5M to deliver the era of Creative BiosciencesBreakout Ventures is excited to announce the launch of our second fund to continue working with incredible entrepreneurs building the…
InBreakout VenturesbyRenee Shenton·Nov 11, 2021Breakout Ventures Grows to Meet Opportunities In Creative BiosciencesExperts in neuroscience and organic chemistry to provide scientific counsel and drive investment growth towards a bio-based future
InBreakout VenturesbyRenee Shenton·Oct 20, 2021The power of single-cell analysisAt Breakout Ventures, we believe cells are the engine of the next decade as the tools, technologies and, most importantly, talent from…
InBreakout VenturesbyRenee Shenton·Jul 29, 2021Breakout 2.0We are excited to share an update on the evolution of Breakout.
InBreakout VenturesbyRenee Shenton·Jun 24, 2021ZymoChem Awarded $4.2 Million from ARPA-E for Transformational Biomanufacturing TechnologyThrough its proprietary biomanufacturing technology, ZymoChem aims to expedite decarbonization of the chemical industry.
InBreakout VenturesbyRenee Shenton·Nov 17, 2020An Easy Pill to SwallowThis week, we’re focusing on the 50th company to join the Breakout Labs portfolio, Glyscend. Glyscend came to us as part of our East Coast…
